Client story: Menarini Diagnostics
One bladder cancer biomarker, different questions from clinicians, hospitals and payers. Discover how Menarini Diagnostics uses live, locally tailored analyses to make its value tangible.
Menarini Diagnostics' urinary biomarker offers a non-invasive way to support surveillance in patients with non-muscle-invasive bladder cancer (NMIBC). But as Dr. Delphine Chabut, Global Head of Medical Affairs & Market Access EMEA at Menarini Diagnostics, put it: clinical efficacy is only the baseline.
Bringing a diagnostic into routine practice requires demonstrating tangible value to urologists, hospital administrators, and payers alike, each of whom asks different questions about the same evidence.
Working with Medip Analytics, Menarini's teams combined their clinical evidence with local data on care pathways, populations, and costs to translate one common evidence base into stakeholder-specific analyses of patient outcomes, cost-effectiveness, budget impact, and resource use, calculated live during conversations with HCPs and payers across markets.
The result: a scalable way to build local evidence, deepen stakeholder engagement, and support informed decisions on adoption and reimbursement. Menarini Diagnostics has since expanded the collaboration to three additional oncology applications.
Request the full client story
Receive the Menarini Diagnostics client story
Enter your email address to receive the full story as a PDF in your inbox.
Your email address will be used to send the requested story. Privacy policy.